Asset Details
Do you wish to reserve the book?
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
Do you wish to request the book?
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
2017
Overview
Monoclonal antibodies （mAbs） blocking immune checkpoint molecules, especially programmed cell death l （PD-1） and its ligands programmed cell death 1 ligand 1 （PD-L1） and ligand 2 （PD-L2）, are currently been in- vestigated for treatment of various tumors [1-3]. PD-L1 and PD-L2 are usually upregulated on the surface of mul- tiple tumor cells to mediate immune tolerance through the interaction with inhibitory PD-1 molecule [4].
